Active Cancer NIHR-supported project Lungs & Breathing
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Gareth Ayre (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
BNT324-01 - A Phase Ib/II, multi-site, open-label,two part trial to evaluate the efficacy,safety, pharmakokinetics,and recommended combination dose of BNT324 with BNT327 in advanced lung cancer
A Phase II, multi-site, randomized, open-label, parallel group trial of BNT327 in combination with chemotherapy for participants with untreated extensive-stage small-cell lung cancer and participants with previously treated small-cell lung cancer
BNT327-01 - A Phase II, multi-site, randomized, open-label, parallel group trial of BNT327 in combination with chemotherapy for participants with extensive-stage small-cell lung cancer and participants with previously treated small-cell lung cancer
A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know